BOSTON--(BUSINESS WIRE)--Crimson Life Sciences (a division of TransPerfect Translations) today announced that it has filed the industry’s first patent for “analyzing, evaluating, and controlling risk of language errors in connection with medical device labeling.” Based on the first ISO 14971-certified risk management system, the filing effectively establishes GMP for labeling translation. The official patent filing provides excellent guidance for translation supplier audits—requests for copies can be sent to: mmiller@crimsonlanguage.com.
